Abstract
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) are severe central nervous system inflammatory demyelinating disorders (CNS IDD) characterized by monophasic or relapsing, longitudinally extensive transverse myelitis (LETM) and/or optic neuritis (ON). A significant proportion of NMOSD patients are seropositive for aquaporin-4 (AQP4) autoantibodies. We compared the AQP4 autoantibody detection rates of tissue-based indirect immunofluorescence assay (IIFA) and cell-based IIFA.MethodsSerum of Chinese CNS IDD patients were assayed for AQP4 autoantibodies by tissue-based IIFA using monkey cerebellum and cell-based IIFA using transfected HEK293 cells which express human AQP4 on their cell membranes.ResultsIn total, 128 CNS IDD patients were studied. We found that 78% of NMO patients were seropositive for AQP4 autoantibodies by cell-based IIFA versus 61% by tissue-based IFA (p = 0.250), 75% of patients having relapsing myelitis (RM) with LETM were seropositive by cell-based IIFA versus 50% by tissue-based IIFA (p = 0.250), and 33% of relapsing ON patients were seropositive by cell-based IIFA versus 22% by tissue-based IIFA (p = 1.000); however the differences were not statistically significant. All patients seropositive by tissue-based IIFA were also seropositive for AQP4 autoantibodies by cell-based IIFA. Among 29 NMOSD patients seropositive for AQP4 autoantibodies by cell-based IIFA, 20 (69%) were seropositive by tissue-based IIFA. The 9 patients seropositive by cell-based IIFA while seronegative by tissue-based IIFA had NMO (3), RM with LETM (3), a single attack of LETM (1), relapsing ON (1) and a single ON attack (1). Among 23 NMO or RM patients seropositive for AQP4 autoantibodies by cell-based IIFA, comparison between those seropositive (n = 17) and seronegative (n = 6) by tissue-based IIFA revealed no differences in clinical and neuroradiological characteristics between the two groups.ConclusionCell-based IIFA is slightly more sensitive than tissue-based IIFA in detection of AQP4 autoantibodies, which are highly specific for NMOSD.
Highlights
Neuromyelitis optica spectrum disorders (NMOSD) are severe central nervous system inflammatory demyelinating disorders (CNS IDD) characterized by monophasic or relapsing, longitudinally extensive transverse myelitis (LETM) and/or optic neuritis (ON)
This is critical for proper long-term treatment of patients, as prompt initiation of immunosuppressive medications such as azathioprine with corticosteroid is indicated in NMOSD to prevent relapse whereas immunomodulatory therapies such as beta-interferon and natalizumab may be indicated in classical multiple sclerosis (CMS) [3,7,25,26,27,28]
A total of 128 patients with CNS IDD consisted of patients with CMS (40), a single attack of acute myelitis (25, two had LETM), NMO (18), relapsing myelitis (15, twelve had LETM), a single attack of ON (14), relapsing ON (9) and a single attack of acute disseminated encephalomyelitis (ADEM) (7)
Summary
Neuromyelitis optica spectrum disorders (NMOSD) are severe central nervous system inflammatory demyelinating disorders (CNS IDD) characterized by monophasic or relapsing, longitudinally extensive transverse myelitis (LETM) and/or optic neuritis (ON). Detection of NMO-IgG or AQP4 autoantibodies is clinically useful for early diagnosis of NMO and its related spectrum disorders (NMOSD), including single attack or recurrent LETM without ON, and recurrent ON without ATM; and especially early distinction between NMOSD and CMS [3]. This is critical for proper long-term treatment of patients, as prompt initiation of immunosuppressive medications such as azathioprine with corticosteroid is indicated in NMOSD to prevent relapse whereas immunomodulatory therapies such as beta-interferon and natalizumab may be indicated in CMS [3,7,25,26,27,28]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.